These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma. Sato J; Kitagawa Y; Yamazaki Y; Hata H; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N J Nucl Med; 2013 Jul; 54(7):1060-5. PubMed ID: 23699668 [TBL] [Abstract][Full Text] [Related]
3. Hypoxic volume evaluated by Sato J; Kitagawa Y; Watanabe S; Asaka T; Ohga N; Hirata K; Shiga T; Satoh A; Tamaki N Int J Oral Maxillofac Surg; 2018 May; 47(5):553-560. PubMed ID: 29030021 [TBL] [Abstract][Full Text] [Related]
4. Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma. Sato J; Kitagawa Y; Yamazaki Y; Hata H; Asaka T; Miyakoshi M; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2031-41. PubMed ID: 24867258 [TBL] [Abstract][Full Text] [Related]
5. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT. Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468 [TBL] [Abstract][Full Text] [Related]
6. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET. Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312 [TBL] [Abstract][Full Text] [Related]
7. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy. Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644 [TBL] [Abstract][Full Text] [Related]
8. [18F]fluoro-2-deoxyglucose-positron emission tomography for the assessment of histopathological response after preoperative chemoradiotherapy in advanced oral squamous cell carcinoma. Shimomura H; Sasahira T; Yamanaka Y; Kurihara M; Imai Y; Tamaki S; Yamakawa N; Shirone N; Hasegawa M; Kuniyasu H; Kirita T Int J Clin Oncol; 2015 Apr; 20(2):308-16. PubMed ID: 24942501 [TBL] [Abstract][Full Text] [Related]
9. SUVmax of FDG-PET correlates with the effects of neoadjuvant chemoradiotherapy for oral squamous cell carcinoma. Miyawaki A; Ikeda R; Hijioka H; Ishida T; Ushiyama M; Nozoe E; Nakamura N Oncol Rep; 2010 May; 23(5):1205-12. PubMed ID: 20372831 [TBL] [Abstract][Full Text] [Related]
10. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778 [TBL] [Abstract][Full Text] [Related]
11. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456 [TBL] [Abstract][Full Text] [Related]
12. Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas. Kawai N; Lin W; Cao WD; Ogawa D; Miyake K; Haba R; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1870-8. PubMed ID: 24781871 [TBL] [Abstract][Full Text] [Related]
13. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours. Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658 [TBL] [Abstract][Full Text] [Related]
14. Yu W; Qiao F; Su X; Zhang D; Wang H; Jiang J; Xu H Biomed Pharmacother; 2019 Nov; 119():109454. PubMed ID: 31526971 [TBL] [Abstract][Full Text] [Related]
15. Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas. Yamada T; Uchida M; Kwang-Lee K; Kitamura N; Yoshimura T; Sasabe E; Yamamoto T Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Apr; 113(4):464-71. PubMed ID: 22676927 [TBL] [Abstract][Full Text] [Related]
16. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis. Bekaert L; Valable S; Lechapt-Zalcman E; Ponte K; Collet S; Constans JM; Levallet G; Bordji K; Petit E; Branger P; Emery E; Manrique A; Barré L; Bernaudin M; Guillamo JS Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1383-1392. PubMed ID: 28315948 [TBL] [Abstract][Full Text] [Related]
17. Assessment of biological parameters in head and neck cancer based on in vivo distribution of Cegla P; Kazmierska J; Gwozdz S; Czepczynski R; Malicki J; Cholewinski W Tumori; 2020 Feb; 106(1):33-38. PubMed ID: 31446858 [TBL] [Abstract][Full Text] [Related]
18. ¹⁸F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with ¹⁸F-FDG PET and immunohistochemistry. Miyashita G; Higuchi T; Oriuchi N; Arisaka Y; Hanaoka H; Tominaga H; Morita S; Miyakubo M; Ishikita T; Nakasone Y; Negishi A; Yokoo S; Endo K Ann Nucl Med; 2010 Oct; 24(8):579-84. PubMed ID: 20652456 [TBL] [Abstract][Full Text] [Related]
19. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor. Toyonaga T; Yamaguchi S; Hirata K; Kobayashi K; Manabe O; Watanabe S; Terasaka S; Kobayashi H; Hattori N; Shiga T; Kuge Y; Tanaka S; Ito YM; Tamaki N Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):611-619. PubMed ID: 27752745 [TBL] [Abstract][Full Text] [Related]
20. The optimal Gertsenshteyn I; Epel B; Ahluwalia A; Kim H; Fan X; Barth E; Zamora M; Markiewicz E; Tsai HM; Sundramoorthy S; Leoni L; Lukens J; Bhuiyan M; Freifelder R; Kucharski A; Giurcanu M; Roman BB; Karczmar G; Kao CM; Halpern H; Chen CT Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4014-4024. PubMed ID: 35792927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]